Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canada Postdoctoral Research Award (CPRA) program

University of Toronto

$140,000.00

Defining the cellular sources and mechanism of BIGH3 in pulmonary fibrosis.

FY 2025-26

Summary
Idiopathic pulmonary fibrosis (IPF) affects 14,000 Canadians per year. IPF is an incurable long-term lung disease where scarring (fibrosis) causes difficulty breathing, decreased quality of life, and shortened lifespan. Existing medications for IPF are not always effective, and development of new therapies have stalled because they have uncontrollable side effects. These failed therapies target a molecule, called 'TGF-B', that causes serious lung scarring, but is required for healthy wound healing. As such, therapies which reduce lung scarring without compromising wound healing are needed. Our research shows that TGF-B requires the presence of another molecule, named 'BIGH3', for lung scarring, suggesting that if we can eliminate BIGH3, we can prevent lung scarring without compromising wound healing. However, the cells that produce BIGH3 and the exact way it drives lung scarring are not understood. In our initial findings, we simulated IPF in mice, and demonstrated that macrophages and fibroblasts, types of immune cells and structural cells, respectively, produce the greatest amount of BIGH3 in the lungs. We also showed that mice genetically engineered to lack BIGH3 are protected from lung scarring during IPF. As a result, we think that macrophages and fibroblasts produce BIGH3 to drive lung scarring. To test this, we will simulate IPF in mice and compare those that can produce BIGH3 to those that have been genetically engineered to lack BIGH3 in macrophages and fibroblasts. We will monitor the level of lung scarring, the frequency of cells that make scar tissue, and the amount of scar tissue forming molecules in these mice. We will also determine the molecules that BIGH3 binds with (called receptors) on scar tissue producing cells. This research will result in new treatment options for Canadians with IPF.
Program
Canada Postdoctoral Research Award (CPRA) program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
537696
Name
Altieri Anthony
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Defining the cellular sources and mechanism of BIGH3 in pulmonary fibrosis.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Fibroblasts; Fibrotic Disease; Immunology; Lung Disease; Macrophages
Abstract
Idiopathic pulmonary fibrosis (IPF) affects 14,000 Canadians per year. IPF is an incurable long-term lung disease where scarring (fibrosis) causes difficulty breathing, decreased quality of life, and shortened lifespan. Existing medications for IPF are not always effective, and development of new therapies have stalled because they have uncontrollable side effects. These failed therapies target a molecule, called 'TGF-B', that causes serious lung scarring, but is required for healthy wound healing. As such, therapies which reduce lung scarring without compromising wound healing are needed. Our research shows that TGF-B requires the presence of another molecule, named 'BIGH3', for lung scarring, suggesting that if we can eliminate BIGH3, we can prevent lung scarring without compromising wound healing. However, the cells that produce BIGH3 and the exact way it drives lung scarring are not understood. In our initial findings, we simulated IPF in mice, and demonstrated that macrophages and fibroblasts, types of immune cells and structural cells, respectively, produce the greatest amount of BIGH3 in the lungs. We also showed that mice genetically engineered to lack BIGH3 are protected from lung scarring during IPF. As a result, we think that macrophages and fibroblasts produce BIGH3 to drive lung scarring. To test this, we will simulate IPF in mice and compare those that can produce BIGH3 to those that have been genetically engineered to lack BIGH3 in macrophages and fibroblasts. We will monitor the level of lung scarring, the frequency of cells that make scar tissue, and the amount of scar tissue forming molecules in these mice. We will also determine the molecules that BIGH3 binds with (called receptors) on scar tissue producing cells. This research will result in new treatment options for Canadians with IPF.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Altieri, Anthony
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~